$Miragen Therapeutics(MGEN)$ Q1 in briefs:

*New ATLL data presented in the first quarter; Company plans to request a meeting with the FDA on a regulatory pathway for cobomarsen in ATLL during Q2 2020

•Additional NIH grant funding released in support of MRG-229 for IPF; preclinical studies progressing as planned with additional data expected to be released Q2 2020

•The SOLAR trial has been impacted by the COVID-19 pandemic; while most clinical sites have remained active, patient monitoring and dosing has been suspended at some sites

•Closed $15.0 million equity offering in February 2020

•Reported $36.1 million in cash and cash equivalents as of March 31, 2020; anticipate cash runway into Q3 2021